Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Structure Therapeutics Strengthens Executive Team With Promotion of Blai Coll, M.D., Ph.D. To Chief Medical Officer and Appointment of Ashley Hall, J.D. As Chief Development Officer

PUBLIC · GPCRSep 17, 2024•over 1 year ago

Position

Chief Development Officer

Company

Structure Therapeutics

Ashley Hall

San FranciscoBiotechnologyTherapeuticsPharmaceuticalBiopharma

Description

Structure Therapeutics Inc announced the promotion of Blai Coll, MD, PhD to Chief Medical Officer, replacing Mark Bach, MD, PhD, and the appointment of Ashley Hall, JD as the Chief Development Officer. These key leadership appointments aim to drive the company's next phase of development and operational success.

Company Information

Company

Structure Therapeutics

Location

601 Gateway Blvd, Suite 900

San Francisco, California, United States

About

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Structure Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months